Tech Company Financing Transactions
Remepy Funding Round
M Ventures, O.G. Tech Ventures and 97212 Ventures participated in a $36 million Series A funding round for Remepy. The funding round was announced on 8/12/2026.
Transaction Overview
Company Name
Announced On
8/12/2026
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Investors
M Ventures (Lead Investor)
O.G. Tech Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its pharmaceutical co-development partnerships, expand its Hybrid Drug pipeline and platform, and fund the global Phase III clinical development of Hybridopa, its lead program for Parkinson's disease.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Ramat Gan, Undisclosed
Israel
Ramat Gan, Undisclosed
Israel
Phone
Undisclosed
Website
Email Address
Overview
Remepy is pioneering hybrid drugs, and redefining combination therapy. Our mission is to bring better personalized care to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Or Shoval
Chief Executive Officer
Michal Tsur
Chief Medical Officer
Shahar Shelly
Chief Operating Officer
Shai Elrich
Chief Scientific Officer
Amir Amedi
Chief Technical Officer
Jonathan Amit-Kanarek
VP - General Counsel
Ofer Tur-Sinai
VP - Product Management
Lior Benderski
Browse more venture capital transactions:
Prev: 8/12/2026: Lovable venture capital transaction
Next: 8/12/2026: Cytix venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs